Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572182 · ClinicalTrials.gov registry record · Phase 1
MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer
A Phase 1 study, sponsored by Pediatric Brain Tumor Consortium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00572182 is a Phase 1 study that was terminated before completion, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 33 participants.
The verdict
NCT00572182, a Phase 1 study, was terminated before completion, sponsored by Pediatric Brain Tumor Consortium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
RATIONALE: MK0752 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of MK0752 in treating young patients with recurrent or refractory CNS cancer.
Interventions
- DRUG MK-0752
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00572182
The ClinicalTrials.gov registry entry for NCT00572182 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MK-0752 is the first listed.
NCT00572182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00572182 about?
NCT00572182 is a clinical study titled "MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer". RATIONALE: MK0752 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of MK0752 in treating young patients with recurrent or refractory CNS cancer.
What is the current status of trial NCT00572182?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2008-07. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00572182?
The interventions under investigation include: MK-0752 (DRUG).
Who is sponsoring clinical trial NCT00572182?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.